Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma
NCT00770315 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma
- Lead sponsor
- ALK-Abelló A/S
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 30, 2009
- Completion date
- May 31, 2011
- Enrollment
- 784 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.